Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.

Current hematologic malignancy reports - 1 Oct 2017

Nazha Aziz, Bejar Rafael

Abstract excerpt

PURPOSE OF REVIEW: The purpose of this study is to review established prognostic models in myelodysplastic syndromes (MDS) and describe how molecular data can be used to improve patient risk stratification. RECENT FINDINGS: Somatic mutations are common in MDS and are associated with disease features including outcomes. Several recurrently mutated genes have prognostic significance independent of risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ASXL1 gene
Share to SRSF2 gene
Share to Models, Biological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 28844082
DOI: 10.1007/s11899-017-0407-9

Genes

ASXL1
IDH2
NRAS
RUNX1
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.PMID 28844082Read ↗

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?Semantic proximity Read ↗

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.Semantic proximity Read ↗

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

Current state of prognostication and risk stratification in myelodysplastic syndromes.Semantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.Semantic proximity Read ↗

Does mutational burden add to other prognostic factors in MDS?Semantic proximity Read ↗

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.Semantic proximity Read ↗

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.Semantic proximity Read ↗

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape.Semantic proximity Read ↗

Prognostic models in myelodysplastic syndromes.Semantic proximity Read ↗

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.